TITLE

COMMENTARY: Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes

AUTHOR(S)
Vella, Adrian
PUB. DATE
January 2008
SOURCE
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author comments on the efficacy of incretin therapy for glycemic control in non-insulin-dependent diabetics. He pointed out that the glucagon-like peptide 1 (GLP1) is associated with a significant incidence of gastrointestinal adverse effects and dipeptidyl peptidase 4 (DDP4) inhibitors are weight-neutral. He suggests that the clinicians and patients must consider the price of the medications for their glucose-lowering efficacy is similar to those established therapies for type 2 diabetes.
ACCESSION #
28694421

 

Related Articles

  • Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes.  // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3 

    The article presents a clinical study that evaluates the efficacy of incretin for glycemic control in adults with non-insulin-dependent diabetes. A randomized-controlled trial showed changes in patients' glycated hemoglobin levels, weight and hypoglycemia. It is concluded that the incretin...

  • Gliptins: A New Class of Oral Antidiabetic Agents. SESHADRI, K. G.; KIRUBHA, M. H. B. // Indian Journal of Pharmaceutical Sciences;2009, Vol. 71 Issue 6, p608 

    India has the largest population of patients with type 2 diabetes mellitus. The conventional agents used to treat type 2 diabetes frequently exhibit reduced efficacy over time leading to inadequate glycaemic control and are also associated with adverse effects. Hence, there is a need for...

  • Nonlinear Increase in GLP-1 Levels in Response to DPP-IV Inhibition in Healthy Adult Subjects. Dai, Haiqinq; Gustavson, Stephanie M.; Calle, Roberto A.; Hirshberg, Boaz // Diabetes;Jun2007 Supplement 1, Vol. 56, pA135 

    Dipeptidyl Peptidase IV (DPP-IV) inhibitors represent a new promising target for the treatment of T2DM. The aim of this study was to investigate the effects of DPP-IV inhibition by PF-00734200, a potent competitive DPP-IV inhibitor, on the dynamics of plasma in healthy adult subjects. In a...

  • Chronic Administration of Alogliptin (SYR-322), a Novel Dipeptidyl Peptidase-IV Inhibitor, Improved Beta-Cell Function in ob/ob Mice. Moritoh, Yusuke; Takeuchi, Koji; Kataoka, Osamu; Asakawa, Tomoko; Odaka, Hiroyuki // Diabetes;Jun2007 Supplement 1, Vol. 56, pA136 

    Alogliptin (SYR-322) is a novel, oral, potent, and highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under development as a once-daily treatment for type 2 diabetes (T2D). The efficacy of alogliptin was investigated in ob/ob mice, an obese model of T2D. Chronic administration of...

  • Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes. Vaidya, H. B.; Goyal, R. K. // Current Drug Targets;Oct2008, Vol. 9 Issue 10, p911 

    Diabetes mellitus (DM) has been recognized as a growing world-wide epidemic by many health advocacy groups including the World Health Organization (WHO). DM affects about 6% of the North American population. A recent report estimated that 8.2% of adult population worldwide has impaired glucose...

  • Long-Acting Glucagon-Like Peptide 1 Receptor Agonists. GARBER, ALAN J. // Diabetes Care;May2011 Supplement 2, Vol. 34, pS279 

    The article examines the efficacy and tolerability of long-acting glucagon-like peptide 1 receptor agonists. The two classes of drugs for treating type 2 diabetes are glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors. A definition of incretin effect is...

  • GLP-1 receptor agonist-induced polyarthritis: a case report. Ambrosio, Maria; Monami, Matteo; Sati, Lavinia; Marchionni, Niccolò; Bari, Mauro; Mannucci, Edoardo // Acta Diabetologica;Aug2014, Vol. 51 Issue 4, p673 

    Occasional cases of bilateral, symmetrical, seronegative polyarthritis have been reported in patients treated with dipeptidyl peptidase-4 inhibitors (Crickx et al. in Rheumatol Int, ). We report here a similar case observed during treatment with a GLP-1 receptor agonist. A 42-year-old man with...

  • Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Russell, Sheldon // International Journal of Clinical Pharmacy;Apr2013, Vol. 35 Issue 2, p159 

    Background Clinical trials comparing incretin-based therapies-glucagon-like peptide-1 receptor agonists (exenatide-twice daily and once weekly-and once-daily liraglutide) and dipeptidyl peptidase-4 inhibitors (vildagliptin, sitagliptin, saxagliptin and linagliptin)-with placebo and oral...

  • Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science. Singh, Awadhesh Kumar // Indian Journal of Endocrinology & Metabolism;Jan/Feb2015, Vol. 19 Issue 1, p182 

    Although GLP-1 (glucagon like peptide-1) based therapies (GLP-1 agonists and dipeptidyl peptidase-4 inhibitors) is currently playing a cornerstone role in the treatment of type 2 diabetes, dilemma does exist about some of its basic physiology. So far, we know that GLP-1 is secreted by the direct...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics